78 related articles for article (PubMed ID: 11316176)
1. Factors predicting interferon treatment response in patients with chronic hepatitis c: late viral clearance does not preclude a sustained response.
Ebeling F; Lappalainen M; Vuoristo M; Nuutinen H; Leino R; Karvonen AL; Lehtola J; Julkunen R; Pohjanpelto P; Färkkilä M
Am J Gastroenterol; 2001 Apr; 96(4):1237-42. PubMed ID: 11316176
[TBL] [Abstract][Full Text] [Related]
2. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
3. [The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study].
Ortiz V; Olaso V; López Viedma B; Córdoba J; Molina JM; Lainez B; Pastor M; Berenguer J
Gastroenterol Hepatol; 1999 Mar; 22(3):122-6. PubMed ID: 10228321
[TBL] [Abstract][Full Text] [Related]
4. Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alpha-interferon therapy.
García-Bengoechea M; Basaras M; Barrio J; Arrese E; Montalvo II; Arenas JI; Cisterna R
Am J Gastroenterol; 1999 Jul; 94(7):1902-5. PubMed ID: 10406257
[TBL] [Abstract][Full Text] [Related]
5. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.
Fukutomi T; Fukutomi M; Iwao M; Watanabe H; Tanabe Y; Hiroshige K; Kinukawa N; Nakamuta M; Nawata H
Med Sci Monit; 2000; 6(4):692-8. PubMed ID: 11208393
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
[TBL] [Abstract][Full Text] [Related]
7. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
[TBL] [Abstract][Full Text] [Related]
8. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Chu CM; Sheen IS; Liaw YF
Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
[TBL] [Abstract][Full Text] [Related]
9. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment.
Bellobuono A; Mondazzi L; Tempini S; Silini E; Idéo G
Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1169-77. PubMed ID: 9471022
[TBL] [Abstract][Full Text] [Related]
10. [Predictive value of a rapid negativity of serum virus C viremia during treatment with interferon alpha in patients with chronic hepatitis C].
Moulin V; Harzic M; Doll J; Dubeaux B; Ghnassia JC; Andrieu J
Pathol Biol (Paris); 1996 May; 44(5):468-72. PubMed ID: 8758497
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation.
Casanovas-Taltavull T; Baliellas C; Benasco C; Serrano TT; Casanova A; Pérez JL; Guerrero L; González MT; Andres E; Gil-Vernet S; Casais LA
Am J Gastroenterol; 2001 Apr; 96(4):1170-7. PubMed ID: 11316166
[TBL] [Abstract][Full Text] [Related]
12. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study.
Fargion S; Fracanzani AL; Rossini A; Borzio M; Riggio O; Belloni G; Bissoli F; Ceriani R; Ballarè M; Massari M; Trischitta C; Fiore P; Orlandi A; Morini L; Mattioli M; Oldani S; Cesana B; Fiorelli G
Am J Gastroenterol; 2002 May; 97(5):1204-10. PubMed ID: 12014729
[TBL] [Abstract][Full Text] [Related]
13. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
14. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
20. Daily interferon therapy for chronic hepatitis C: a report of a community practice experience.
Srinivas D; Mani H; Crumpler C; Van Thiel DH
Hepatogastroenterology; 2002; 49(46):1053-7. PubMed ID: 12143200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
